Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 3/20 | 0.41 |
| ▸ | KDR | P35968 | 3/20 | 0.41 |
| ▸ | PDE2A | O00408 | 2/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | LSS | P48449 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14973035 | 0.84 | ASPH (0.42) | MAPTFLT1KDRPDE2AKDM4E | |
| SCHEMBL14973107 | 0.83 | KDM4E (0.43) | MAPTFLT1KDRPDE2AKDM4E | |
| SCHEMBL14973190 | 0.83 | SLC6A5 (0.43) | MAPTALDH1A1 | |
| SCHEMBL14973162 | 0.82 | MEN1 (0.46) | MAPT | |
| Hydrochloric Acid SCHEMBL14973129 | 0.82 | SLC6A5 (0.42) | MAPTALDH1A1 | |
| SCHEMBL14973069 | 0.81 | PDE2A (0.41) | MAPTFLT1KDRPDE2ANR3C2 | |
| SCHEMBL14973210 | 0.79 | MAPT (0.50) | MAPTKDM4EALDH1A1 | |
| SCHEMBL14973308 | 0.79 | PDE2A (0.38) | MAPTFLT1KDRPDE2ANR3C2 | |
| SCHEMBL14973113 | 0.79 | PTGS2 (0.41) | MAPTALDH1A1 | |
| SCHEMBL14973071 | 0.76 | PDE2A (0.39) | MAPTFLT1KDRPDE2ANR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2604602-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | GRIN2C, GRIN2B, GRIN3A | MAPT 129/4885FLT1 4816/4885KDR 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.